Lidocaine Accord (Lidocaine Hydrochloride)

Lidocaine blocks voltage‑gated sodium channels on nerve membranes, preventing the rapid influx of sodium that is required for depolarisation. This inhibition stops the generation and propagation of action potentials, thereby interrupting pain signal transmission and producing a reversible loss of sensation in the treated area.

The dose of Lidocaine Accord is determined by the prescribing clinician based on the intended route, the procedure, patient weight, and overall health status. Only a qualified health professional should set the dosage and administration schedule.

Safety data for Lidocaine Accord in pregnancy and lactation are limited, and the product’s pregnancy category is listed as unknown. Use during pregnancy or while breastfeeding should only occur if the potential benefit justifies any potential risk, and after consultation with a healthcare provider.

To request Lidocaine Accord, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and any required import documentation.

Lidocaine is an amide‑type local anesthetic with a rapid onset and moderate duration of action, making it suitable for both short procedures and continuous infusions. Compared with ester‑type agents such as procaine, lidocaine has a lower risk of allergic reactions and is metabolised primarily by the liver, allowing more predictable dosing in most patients.

Lidocaine Accord should be stored at room temperature, below 25 °C, in its original packaging. Protect the solution from direct light, moisture and extreme temperature fluctuations. Do not freeze the product, and keep it out of reach of children.

Lidocaine Accord is administered by a qualified professional via epidural, intramuscular or intravenous injection, depending on the clinical indication. The solution is injected directly into the target tissue or vascular compartment, and the volume and concentration are adjusted according to the procedure and patient characteristics.

Serious adverse events include seizures, severe cardiac arrhythmias such as ventricular tachycardia, respiratory depression, anaphylactic reactions, methemoglobinemia, and cardiovascular collapse. These risks increase with high plasma concentrations, rapid intravenous injection, or when combined with other drugs that affect cardiac conduction.

Lidocaine Accord should be avoided in patients with a known hypersensitivity to lidocaine or other amide‑type anesthetics, in individuals with severe heart block or uncontrolled arrhythmias unless the benefit outweighs the risk, and in patients with significant hepatic impairment without dose adjustment. Clinical judgment is essential for all contraindications.